CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 60 enrolled
Drug / intervention
Long-Acting Methylphenidatedrug
Likely dose
Long-Acting Methylphenidate 76 milligramfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00783835
NCT00783835Phase 4Completed
CompareCT.gov

A Multicenter Open Trial to Evaluate the Effectiveness and Quality of Life in Adults With Attention Deficit /Hyperactivity Disorder (ADHD) Treated With Long Acting Methylphenidate (CONCERTA)

Janssen-Cilag Farmaceutica Ltda.·interventional·Posted Nov 3, 2008·Updated Jul 23, 2013

In Brief

A Phase 4 clinical trial evaluating Long-Acting Methylphenidate for Attention Deficit Hyperactivity Disorder. Completed, enrolled 60 participants across 5 sites.

Detailed Summary

The purpose of this study is to evaluate the efficacy, safety and to assess the impact of the treatment on quality of life of long-acting methylphenidate in adult participants with Attention Deficit Hyperactivity Disorder (ADHD). ADHD is a clinical condition beginning in childhood and is characterized by inadequate levels of attention, hyperactivity and impulsiveness.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAttention Deficit Hyperactivity Disorder
CountriesBrazil
Collaborators--

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 3, 2008
Enrollment StartFeb 1, 2008
Primary CompletionOct 1, 2008
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 17.7 years ago

Interventions

Long-Acting Methylphenidatedrug

Long-Acting Methylphenidate within the range of 18, 36, 54 and 76 milligram will be orally administered once daily up to Day 56.